header-logo header-logo

Patent

07 October 2016
Issue: 7717 / Categories: Case law , Law digest , In Court
printer mail-detail

Fujifilm Kyowa Kirin Biologics Company Ltd v Abbvie Biotechnology Ltd and another [2016] All ER (D) 10 (Oct)

The Patents Court, in the course of a dispute concerning the ability of the claimant company (FKB) to launch a generic drug of its own once the defendants’ supplementary protection certificate had expired, dismissed the defendants’ application for summary judgment. It held that FKB had a real prospect of success and that the UK courts had jurisdiction over FKB’s application for a declaration against the first defendant.

If you are not a subscriber, subscribe now to read this content
If you are already a subscriber sign in
...or Register for two weeks' free access to subscriber content

MOVERS & SHAKERS

FOIL—Bridget Tatham

FOIL—Bridget Tatham

Forum of Insurance Lawyers elects president for 2026

Gibson Dunn—Robbie Sinclair

Gibson Dunn—Robbie Sinclair

Partner joinslabour and employment practice in London

Muckle LLP—Ella Johnson

Muckle LLP—Ella Johnson

Real estate dispute resolution team welcomes newly qualified solicitor

NEWS
Solicitors are installing panic buttons and thumb print scanners due to ‘systemic and rising’ intimidation including death and arson threats from clients
Ministers’ decision to scrap plans for their Labour manifesto pledge of day one protection from unfair dismissal was entirely predictable, employment lawyers have said
Cryptocurrency is reshaping financial remedy cases, warns Robert Webster of Maguire Family Law in NLJ this week. Digital assets—concealable, volatile and hard to trace—are fuelling suspicions of hidden wealth, yet Form E still lacks a section for crypto-disclosure
NLJ columnist Stephen Gold surveys a flurry of procedural reforms in his latest 'Civil way' column
Paper cyber-incident plans are useless once ransomware strikes, argues Jack Morris of Epiq in NLJ this week
back-to-top-scroll